TRP
data caveat$7M12mo
Tissue Repair
Biotechnology · Dermatology
Licensed RGTA (ReGeneraTing Agent) technology for wound healing and tissue repair. CACIPLIQ20 product in Phase 3 for scars.
Data HealthTrials1 of 1 active · stale enrollment
Cash data from Mar 2026 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$6.7M
Mar 2026 4C
Runway
12moADEQUATE
Based on Mar 2026 4C
Market Cap
$7M
Burn Rate
$1.7M/qtr
Mar 2026 4C
Shares Outstanding
60M
Pipeline Assets
2
Latest Insightprice-sensitive announcements & broker notes
Price-sensitiveQuarterly 4C30 Apr 2026
Quarterly Activities/Appendix 4C Cash Flow Report
Cash$6.7M·Burn$1.7M/q·OCF$-1.7M
3M Price
TRP.ASX$0.110-31.3% 3M
Low $0.105High $0.170
Pipeline Assets (2)
Discovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
NDA
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Other ticker dataInsider activity, holders, grants, publications
expand ›
Insider activity, holders, grants, publications
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
expand_moreClinical Publications
Peer-reviewed papers & conference abstracts via PubMed
10 papers
Clinical Publications
Peer-reviewed papers & conference abstracts via PubMed
Int J Low Extrem Wounds2026-06· RGTA
Catalysts (1)
TRIVIA Phase 3 interim analysis (100 patients)
UpcomingExpectedarrow_upwardHigh31 July 2026
| Event | Type | Confidence | Impact | Date | Status |
|---|---|---|---|---|---|
| TRIVIA Phase 3 interim analysis (100 patients) Binary go/no-go at 100 patients. Currently ~40 enrolled. Determines whether Phase 3 program continues | data readout | Expected | arrow_upwardHigh | 31 July 2026 | Upcoming |
Track RecordDelivery Consistency Index
expand ›
Delivery Consistency Index
Historical delivery and spending consistency. Data is limited for recently added companies.
Delivery Consistency Index
Delivery
–Insufficient data
0/3 data points needed
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
High95/100(limited data)
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Filed 2 of 2 4Cs on time· statutory deadline
What drove these scores · rolling 2yr
arrow_drop_up
Stable burn rate — 12% quarterly variation — consistent spend
·
Phase 3+ thresholds — Burn rate variability thresholds adjusted for late-stage development
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
Clinical Trials(6)
1 activeClinicalTrials.gov ↗
Ph2Not Yet RecruitingEnrollment stale · 494d
OTR4132Placebo
A Trial to Assess the Efficacy and Safety of OTR4132-MD in Patients with Acute Ischemic Stroke
Endovascular Thrombectomy · Ischemic Cerebrovascular Accident
RandomizedQuadruple Blind18 Years – 85 Years
Primary endpoint Baseline-Adjusted 24-Hour NIHSS
ENROL60
no manual snapshots — enter via record_enrollment.py
Announcements(8)
payments
Quarterly 4CPSauto_awesome
Quarterly Activities/Appendix 4C Cash Flow Report30 Apr 2026
expand_more421KB